Angeliki Makri1, Srivandana Akshintala2,3, Claudia Derse-Anthony4, Jaydira Del Rivero2, Brigitte Widemann2, Constantine A Stratakis1, John Glod2, Maya Lodish1. 1. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health, Bethesda, Maryland. 2. National Cancer Institute, Bethesda, Maryland. 3. Division of Pediatric Hematology/Oncology, School of Medicine, New York University, New York, New York. 4. Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland.
Abstract
Context: Multiple endocrine neoplasia type 2B (MEN2B) is characterized by early-onset medullary thyroid cancer in virtually all cases and a 50% lifetime risk of pheochromocytoma (PHEO) development. The literature on PHEO in patients with MEN2B is limited with most data being reported from adult studies that primarily address MEN2A. Objective: The aim of the current study is to describe PHEO development in a cohort of pediatric patients with MEN2B. Design: Retrospective chart review of patients with MEN2B evaluated at the National Institutes of Health in the period between July 2007 and February 2018. Results: A total of 38 patients were identified (21 males and 17 females). Mean age at MEN2B diagnosis was 10.6 ± 3.9 years. Eight patients (21%) developed PHEO in the course of follow-up to date, all of whom were sporadic cases with the classic M918T RET mutation. PHEO was diagnosed based on biochemical and/or imaging screening studies in five patients, whereas three patients presented with symptoms of excess catecholamines. PHEO was diagnosed at a mean age 15.2 ± 4.6 (range, 10 to 25) years and 4.0 ± 3.3 years after MEN2B diagnosis. Only one patient was diagnosed with PHEO as the initial manifestation of MEN2B after she presented with hypertension and secondary amenorrhea. Conclusion: Undiagnosed PHEO can be associated with substantial morbidity. Current American Thyroid Association guidelines recommend PHEO screening starting at age 11 for the high-/highest risk group. The youngest patient diagnosed with PHEO in our cohort was an asymptomatic 10-year-old, suggesting that PHEO development may begin before the screening-recommended age of 11, though remains clinically undetectable and thus the current screening guidelines seem appropriate.
Context:Multiple endocrine neoplasia type 2B (MEN2B) is characterized by early-onset medullary thyroid cancer in virtually all cases and a 50% lifetime risk of pheochromocytoma (PHEO) development. The literature on PHEO in patients with MEN2B is limited with most data being reported from adult studies that primarily address MEN2A. Objective: The aim of the current study is to describe PHEO development in a cohort of pediatric patients with MEN2B. Design: Retrospective chart review of patients with MEN2B evaluated at the National Institutes of Health in the period between July 2007 and February 2018. Results: A total of 38 patients were identified (21 males and 17 females). Mean age at MEN2B diagnosis was 10.6 ± 3.9 years. Eight patients (21%) developed PHEO in the course of follow-up to date, all of whom were sporadic cases with the classic M918TRET mutation. PHEO was diagnosed based on biochemical and/or imaging screening studies in five patients, whereas three patients presented with symptoms of excess catecholamines. PHEO was diagnosed at a mean age 15.2 ± 4.6 (range, 10 to 25) years and 4.0 ± 3.3 years after MEN2B diagnosis. Only one patient was diagnosed with PHEO as the initial manifestation of MEN2B after she presented with hypertension and secondary amenorrhea. Conclusion: Undiagnosed PHEO can be associated with substantial morbidity. Current American Thyroid Association guidelines recommend PHEO screening starting at age 11 for the high-/highest risk group. The youngest patient diagnosed with PHEO in our cohort was an asymptomatic 10-year-old, suggesting that PHEO development may begin before the screening-recommended age of 11, though remains clinically undetectable and thus the current screening guidelines seem appropriate.
Authors: Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack Journal: Thyroid Date: 2015-06 Impact factor: 6.568
Authors: L Nguyen; P Niccoli-Sire; P Caron; D Bastie; B Maes; G Chabrier; O Chabre; V Rohmer; P Lecomte; J F Henry; B Conte-Devolx Journal: Eur J Endocrinol Date: 2001-01 Impact factor: 6.664
Authors: Michael Brauckhoff; Andreas Machens; Sören Hess; Kerstin Lorenz; Oliver Gimm; Katrin Brauckhoff; Carsten Sekulla; Henning Dralle Journal: Surgery Date: 2008-12 Impact factor: 3.982
Authors: O Gimm; D J Marsh; S D Andrew; A Frilling; P L Dahia; L M Mulligan; J D Zajac; B G Robinson; C Eng Journal: J Clin Endocrinol Metab Date: 1997-11 Impact factor: 5.958
Authors: Jennifer Bryant; Jennifer Farmer; Lisa J Kessler; Raymond R Townsend; Katherine L Nathanson Journal: J Natl Cancer Inst Date: 2003-08-20 Impact factor: 13.506
Authors: C Eng; D P Smith; L M Mulligan; M A Nagai; C S Healey; M A Ponder; E Gardner; G F Scheumann; C E Jackson; A Tunnacliffe Journal: Hum Mol Genet Date: 1994-02 Impact factor: 6.150
Authors: K M Carlson; S Dou; D Chi; N Scavarda; K Toshima; C E Jackson; S A Wells; P J Goodfellow; H Donis-Keller Journal: Proc Natl Acad Sci U S A Date: 1994-02-15 Impact factor: 11.205
Authors: Michael Brauckhoff; Andreas Machens; Kerstin Lorenz; Trine Bjøro; Jan Erik Varhaug; Henning Dralle Journal: Ann Surg Date: 2014-04 Impact factor: 12.969